Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$4.6 - $7.8 $65,425 - $110,939
-14,223 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$6.1 - $10.2 $66,191 - $110,680
-10,851 Reduced 43.28%
14,223 $9,000
Q3 2021

Nov 15, 2021

BUY
$8.2 - $12.4 $205,606 - $310,917
25,074 New
25,074 $23,000

About Cellectar Biosciences, Inc.


  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $1.59M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Two Sigma Securities, LLC Portfolio

Follow Two Sigma Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Securities, LLC with notifications on news.